CO VALACYCLOVIR TABLET

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE)

可用日期:

COBALT PHARMACEUTICALS COMPANY

ATC代码:

J05AB11

INN（国际名称）:

VALACICLOVIR

剂量:

1000MG

药物剂型:

TABLET

组成:

VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 1000MG

给药途径:

ORAL

每包单位数:

21/30/100

处方类型:

Prescription

治疗领域:

NUCLEOSIDES AND NUCLEOTIDES

產品總結:

Active ingredient group (AIG) number: 0128626003; AHFS:

授权状态:

CANCELLED PRE MARKET

授权日期:

2017-09-01

产品特点

_ _
_ _
_Page 1 of 40_
PRODUCT MONOGRAPH
PR
_CO _VALACYCLOVIR
Valacyclovir Hydrochloride Tablets
500 mg and 1000 mg valacyclovir (as valacyclovir hydrochloride)
Antiviral Agent
Actavis Pharma Company
6733 Mississauga Road, Suite 400
Mississauga, Ontario
L5N 6J5
Date of Revision:
February 01, 2016
Control No.: 191484
_ _
_ _
_Page 2 of 40_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
7
DRUG INTERACTIONS
.................................................................................................
13
DOSAGE AND ADMINISTRATION
.............................................................................
14
OVERDOSAGE
...............................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 17
STORAGE AND STABILITY
.........................................................................................
18
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 19
PART II: SCIENTIFIC INFORMATION
..............................................................................
20
PHARMACEUTICAL INFORMATION
.........................................................................
20
CLINICAL TRIALS
.........................................................................................................
21
DETAILED PHARMACOLOGY
...............